Latest insights

The King has granted a posthumous conditional pardon to Ruth Ellis, the last woman executed in the UK, recognising historic injustice and domestic abuse.

Daniel Naftalin has taken up his role as Mishcon de Reya’s new Managing Partner. Daniel was elected by partners earlier this year and takes over today from outgoing Managing Partner James Libson following a transition period.

The EU Corporate Sustainability Reporting Directive (CSRD) applies to companies and groups headquartered outside the EU, if they generate more than €450 million in EU turnover and have an EU subsidiary or branch with turnover exceeding €200 million.

As charities and foundations operate in increasingly complex and high-risk environments, legal, governance and compliance considerations have become central to delivering impact.

Despite ongoing peace talks, the conflict in Iran is already giving rise to disputes, including a recent case before the English High Court. We are likely to see further litigation emerge, especially if the current phase of negotiations fails.

R v Osmond is the first reported case which considers the elements of the tipping off offence under Part 7 of the Proceeds of Crime Act 2002 ('POCA 2002').

Mishcon de Reya has advised Pixel-Flo Ltd on its £5.25 million seed funding round, led by Northern Gritstone with additional investment from SCVC, the Parkwalk Northern Universities Venture Fund and HTGF.

The European Commission has published the final version of its Guidelines on the transparency obligations under the EU AI Act, which largely apply from 2 August 2026. This contains a number of important clarifications and updates compared to the draft version issued in May.

Anthropic supports open AI models where risks are limited, but proposes tighter chip export controls, action against large-scale model copying and mandatory safety testing for sufficiently powerful models.

Mishcon de Reya has advised Relation Therapeutics on its $110 million collaboration with GSK.  The strategic research collaboration with GSK is focused on generating large-scale human cellular perturbation data and deploying them into models, including MORGAN, Relation's cellular biology foundation model, to deepen understanding of disease biology and support the discovery of potential new therapeutic targets.

In a recent piece for Building magazine, Planning Partner Nicholle Kingsley comments on Barbican Quarter Organisation Ltd vs City of London Corporation